
Dr. Charles Mok (speaker) argues that the FDA’s claim that testosterone therapy increases cardiovascular risk is unsupported. He says the FDA based the claim on one faulty/retracted paper, cites a large 2016 study of about 83,000 men followed for six years (≈480,000 person-years), and references a Veterans Affairs (VA) analysis reporting that men receiving testosterone replacement had roughly half the mortality (including cardiovascular) compared with untreated men. The speaker’s stance: testosterone replacement decreases all-cause and cardiovascular mortality.
Questions this video answers
2016
About 83,000 men
Six years
Approximately 480,000 person-years (83,000 men × 6 years)
They were reported to be about half as likely to be dead (≈50% lower all-cause and mainly cardiovascular mortality) compared with men who did not receive testosterone replacement.










